R. Balheda

Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials

X. Paoletti, J. Soria, V. Ribrag, 2018, Investigational New Drugs.

Rhinitis and epistaxis in patients treated by anti-angiogenic therapy

J. Soria, E. Escudier, C. Massard, 2009, Investigational New Drugs.

Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system

J. Soria, S. de Botton, V. Ribrag, 2014, Anti-cancer drugs.

A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors 



G. Kroemer, J. Soria, J. Armand, 2011, Cell cycle.

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.

E. Solary, O. Mir, T. de Baère, 2018, European journal of cancer.

Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers

E. Solary, T. de Baère, S. Michiels, 2018, Oncotarget.